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Immune toleranceThe aim of this study was to investigate whether early phase of acute respiratory distress syndrome (ARDS)
is associated with changes in immune response, either systemic or localized to the lung. ARDS and control
mechanically ventilated patients, as well as healthy volunteers were studied. Alveolar macrophages (AMΦ)
and blood monocytes (BM) were treated ex vivo with lipopolysaccharide (LPS), interferon-γ (IFNγ), and
surfactant. Phospholipase A2 (PLA2) activity and TLR4 expression were evaluated as markers of cell response.
AMΦ from ARDS patients did not respond upon treatment with either LPS or IFN-γ by inducing PLA2
production. On the contrary, upon stimulation, in control patients the intracellular PLA2, (mainly cPLA2)
levels were increased, but secretion of PLA2 (mainly sPLA2-IIA) was observed only after treatment with LPS.
Surfactant suppressed PLA2 production in cells from both groups of patients. Increased relative changes of
total PLA2 activity and an upregulation of TLR4 expression upon stimulation was observed in BM from
primary ARDS, control patients and healthy volunteers. In BM from secondary ARDS patients, however, no
PLA2 induction was observed, with a concomitant down-regulation of TLR4 expression. Cytosolic PLA2, its
activated form, p-cPLA2, and sPLA2-IIA were the predominant PLA2 types within the cells, while
extracellularly only sPLA2-IIA was identiﬁed. These results support the concept of down-regulated innate
immunity in early ARDS that is compartmentalized in primary and systemic in secondary ARDS. PLA2
isoforms could serve as markers of the immunity status in ARDS. Finally, our data highlight the role of
surfactant in controlling inﬂammation.iversity of Ioannina, 451 10
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The close association between an explosive inﬂammatory reaction
and pulmonary oedema outlines acute respiratory distress syndrome
(ARDS) [1]. The injury to the alveolo-capillary barrier is triggered by a
direct (such as aspiration or pneumonia) or indirect (as in sepsis or
trauma) insult to the lung. Accordingly, ARDS is deﬁned as primary or
secondary. The ultimate inﬂammatory response in the lungs probably
depends on the balance between pro-inﬂammatory and compensa-
tory anti-inﬂammatory factors. Anti-inﬂammatory mediators disrupt
inﬂammatory reaction, intervene in monocytes and macrophages
function and, if left unopposed, lead to immunosuppression [2].
Alveolar macrophages (AMΦ) are key effector cells that represent
the ﬁrst line of pulmonary defence. They can be either resident in the
lung parenchyma or recruited from the circulation [3]. During acute
lung injury AMΦ get activated and interact with the alveolar epithelialcells, while circulating monocytes interact with endothelial cells
within the endovascular space. AMΦ and blood monocytes (BM) are
activated by a wide variety of agents, such as lipopolysaccharide (LPS)
and interferon-γ (IFN-γ) and are able to produce mediators including
arachidonic acid, which is liberated from cell membranes through the
action of phospholipase A2 (PLA2). LPS is a cell wall component from
gram-negative bacteria that triggers cellular responses through CD14
and toll-like receptors (TLRs), typically TLR4, on macrophages and
monocytes [4]. TLR4 up-regulation leads to an excessive production of
biologically-active substances, including PLA2s [5]. IFNγ is an
important immune-activating cytokine that primes macrophages
through the JAK-STAT pathway and induces expression of cytosolic
PLA2 [6,7].
Phospholipases A2, an ubiquitous superfamily of enzymes impli-
cated in various inﬂammatory processes, catalyze the hydrolysis of
membrane phospholipids generating pro-inﬂammatory eicosanoids,
arachidonic acid and platelet activating factor (PAF). Cytosolic PLA2
(cPLA2) catalyses the intracellular arachidonic acid release, while
secretory types of PLA2, such as groups IIA and V, are involved in
extracellular arachidonic acid release [8–10]. Secretory phospholi-
pases A2 can affect pulmonary function either directly, by hydrolysing
surfactant phospholipids or indirectly, by producing biologically-
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implicated in immunomodulation associated with ARDS, while it has
been suggested that type-II secretory PLA2 in ARDS derives primarily
from alveolar macrophages [11–13].
Lung surfactant contributes to lung integrity by reducing surface
tension at the air–liquid interphase of alveolar epithelium. It is
composed by speciﬁc proteins and lipids. Although there is ample
evidence on the role of surfactant proteins in controlling inﬂamma-
tion [14], little is known about the effect of surfactant lipids on
immune cell function.
In this studywe investigatedwhether early ARDS is associatedwith
impaired immune response, either systemic or localized to the lung
andwhether PLA2 can serve as a reliablemarker to follow the immune
status. This was accomplished by ex vivo stimulating AMΦ and BM
from ARDS and control patients by LPS or IFNγ with and without the
presence of surfactant and by measuring their ability to induce PLA2
isotypes production and secretion as well as TLR-4 expression.
2. Materials and methods
2.1. Patients
Forty-one consecutive mechanically ventilated patients were
employed in this study, 27 with early ARDS (14 with primary and
13with secondary), and 14 control patients. Bloodmonocytes isolated
from 9 healthy volunteers, matched in age with the ARDS patients
were tested as well. Standard criteria for ARDS diagnosis were based
on the American-European Consensus [15]. The ﬁrst 48 h from the
initiation of ARDS are considered as early stage of the syndrome. The
causes of primary ARDSwere pneumonia, aspiration of gastric content
and lung contusion. The risk factors for secondary ARDS were severe
sepsis due to catheter-related infections, abdominal sepsis and pan-
creatitis. The control group included intubated and mechanically-
ventilated patients with neuromuscular diseases who developed
ventilatory failure. The inclusion criteria for control subjects were: no
evidence of cardiopulmonary disease, normal chest radiograph and
PaO2/FiO2N300 mm Hg without evidence of systemic inﬂammation.
The patients’ demographic, clinical and laboratory data are shown in
(Table 1).
The analyses were performed in bronchoalveolar lavage (BAL)
ﬂuid obtained by ﬁberoptic bronchoscopy [11] and in arterial blood.
The samples were collected within 24 h following the diagnosis of
ARDS.
The protocol was approved by the review board for human studies
of the University Hospital of Ioannina. The patients or the next of kin
gave a written informed consent to the study.Table 1
Clinical Data of primary (P), secondary (S) ARDS and control patients.
ARDS P p Value
P vs. S
Age, years 46±18 NS
Male/female 4/14 NS
PO2/FiO2 139±52* NS
PCO2 45±14 NS
Tidal volume 433±80* NS
PEEP 11.5±3.9* NS
Length of stay in ICU (days) 12.5±7.0 NS
Risk factors
• Pneumonia, 4
• Aspiration of gastric content 6
• Lung contusion 4
• Catheter-related infections
• Abdominal sepsis
• Pancreatitis2.2. Cell isolation
BAL was ﬁltered for mucus removal and centrifuged at 500g for
10 min at 4 °C for cell isolation. Cells were washed twice with
phosphate buffer solution (PBS), pH 7.4 and ﬁnally re-suspended in
RPMI. Cell count and viability were measured by Trypan Blue
exclusion dye. For monocytes isolation, 20 mL of heparinized whole
blood were collected and diluted with an equal volume of PBS.
Portions from the diluted blood samples (6 mL) were layered on top
of 5 mL of Ficoll-Paque solution and centrifuged at 400g for 30 min at
20 °C. The upper layer was discarded and monocytes layer was
collected, centrifuged, the cells were washed twice with PBS and
ﬁnally re-suspended in RPMI. Alveolar macrophages and blood
monocyte populations were further puriﬁed by a negative-isolation
protocol, using dynabeads (Dynal LTD, UK).
2.3. Cell cultures and experimental design
Cell number was adjusted at 1×106 cells/well and allowed to
adhere in 24-well plates for 3 h, at 37 °C in a 5% CO2 incubator. The
growthmedium consisted of RPMI-1640 without phenol red (to avoid
interference with the ﬂuorimetric assays), supplemented with 10%
FBS, 2 mM L-glutamine, Ca2+/Mg2+ and antibiotics cocktail. After the
3-h incubation each well's supernatant was collected, while adherent
cells were washed twice with 37 °C PBS and incubated for 20 h in
RPMI-1640, without phenol red, nor FBS. Cells were treated with LPS,
(25 μg/mL, Sigma, Saint Louis, USA), IFN-γ (Imukin, 300 U/mL,
Boehringer Ingelheim, am Rhein, Germany), Lung surfactant (Sur-
vanta 62.5 μg phospholipids/mL, Αbbott Laboratories, Chicago, Illi-
nois), a commercial type of lung surfactant and combinations of the
above. Untreated cells were used as controls. When the combination
of surfactant with activators was applied in the cell culture, the
activators were added ﬁrst, followed by surfactant addition after
15 min. After the incubation period, supernatants were collected and
centrifuged to remove sediment. Adherent cells were scraped off the
Petri dish, harvested, washed twice with PBS and re-suspended in
1 mL PBS. Cells and cell supernatants were aliquoted and kept at
−80 °C for further analyses. For blotting experiments, cells were
obtained directly from the dish with 50 μL of electrophoresis sample
buffer. Total protein was determined by the method of Bradford [16].
2.4. PLA2 ﬂuorimetric determination
PLA2 total activity was measured in cell supernatants and in the
adherent cell homogenates with a ﬂuorimetric method, using C12-NBD-
PC as substrate [17]. The incubation buffer contained Tris–HCl buffer,ARDS S Control p Value
C vs. P or S
50±24 44±22 NS
3/13 2/11 NS
153±44* 375±39 b0.01
43±11 37±9 NS
461±69* 619±105 0.05
10.6±2.8* 3±2 0.05
15.5±8.9 18.6±9.2 NS
3
6
4
Fig. 1. Relative changes of total PLA2 activity in alveolar macrophages (AMΦ) from
primary, secondary ARDS and control patients after ex vivo challenge. Cells were
isolated from the BAL ﬂuid of intubated patients with primary, secondary ARDS and
patients without cardiopulmonary disease (controls). AMΦ were isolated as described
in Materials and methods. After FBS removal, the cells were treated for 20 h with
LPS (25 μg/mL), IFN-γ (300 U/mL), combinations of LPS with surfactant (62.5 μg
phospholipids/mL) or IFN-γ with surfactant. Intracellular PLA2 activity was quantiﬁed
in cell homogenates ﬂuorimetrically. Data are expressed as Mean±SEM of the percent
difference between untreated (baseline) and treated cells. Statistically signiﬁcant
differences (pb0.05) are marked as follows: (*): Treated vs. Untreated cells;
(†): Primary ARDS vs. Control; (‡): Secondary ARDS vs. Control; (●): Control cells
pretreated with surfactant and challenged with LPS or INF-γ vs. Control cells challenged
with LPS or IFN-γ. The exact p values are presented in the text or in Table 2.
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reaction was performed in white, opaque microELISA plates and was
initiated by the addition of 100 μl sample (maximum protein concen-
tration: 25 μg/mL). The increase of ﬂuorescence intensity was contin-
uouslymonitored for 3 h by an LS-55 Perking-Elmer spectroﬂuorimeter
and the enzymic activity was quantiﬁed by using authentic C12-NBD-FA
as internal standard. The resultswere expressed as percent difference of
PLA2 activity, [(PLA2(treated)−PLA2(untreated))/PLA2(untreated)]×100, con-
sidering as zero the values of the untreated cells (baseline) under the
given conditions. With this assay the total activity of all the PLA2
isoenzymes, including cPLA2 and sPLA2 with preference to long acyl
chains and Ca2+ are co-determined.
2.5. PLA2 isoenzymes
Secretory PLA2 type IIA, cytosolic (c) PLA2 and its activated form
p-cPLA2were identiﬁed by immunoblotting: Sampleswere subjected to
SDS-PAGE, followed by blotting onto a PVDF membrane. Nonspeciﬁc
binding sites were blocked by incubation with 5% skim milk in TBS
containing 0.1% Tween-20 (TBS-T), for 1 h at room temperature. The
membraneswere then incubatedwith the appropriate antibody for 2 h:
polyclonal rabbit anti-human cPLA2 (dilution 1:1000), polyclonal rabbit
anti-human phosphorylated cPLA2 antibody (Ser 505) (dilution
1:1000), Cell Signalling Technology, (Beverly, MA, USA) or mouse
anti-human sPLA2 group IIA. Equal loading was estimated by using
mouse anti-human β-actin (Santa-Cruz, CA, USA). After washing with
TBS-T, themembranes were incubated for 1 h with peroxidase-labelled
anti-rabbit (Santa-Cruz, CA, USA) or anti-mouse antibodies (Thermo-
Scientiﬁc Pierce antibodies, USA). After rinsing with TBS-T, the
immunoreactive bands were visualized using a chemiluminescence
detection kit. Densities of the bands were plotted with Image J (U.S.
National Institutes of Health, Bethesda, Maryland, USA). Equal protein
loading was conﬁrmed by using anti-actin antibody (Santa-Cruz,
California USA).
2.6. TLR4 expression
After cell adherence and the 20-h incubation, cells were harvested
with a scraper to avoid surface receptors destruction and washed twice
with cold PBS, as previously stated. Cells were re-suspender in 300 μl
PBS. TLR4 cell surface expression was measured by staining the cells for
30 min, at 4 °C in the darkwith an anti-hTLR4 (HTA125-PE conjugated)
antibody (e-Biosciences, San Diego, USA), while a mouse PE-IgG1
isotype control antibody (BD Biosciences, Belgium) was used as a
negative control. Thereafter, cells were subjected to ﬂow cytometric
analysis on a FACSCalibur System (Becton Dickinson, USA). The results
were expressed: (1) as Mean Fluorescence Intensity (MFI), in arbitrary
units, representing the absolute value of the expression of each receptor
and (2) as percent difference in comparison to the control. The MFI
values of the isotype negative controls were subtracted from the
samples' respective MFI.
2.7. Statistics
Statistical analysis was performed using the Statistical Package for
Social Sciences version 13 for Windows (SPSS Inc., Chicago, Illinois,
USA). Data were tested for normality with the Kolmogorov–Smirnov
test and presented as (mean±SD) or (median±range), as appropri-
ate. All variables were normally distributed. Comparison between
baseline and post treatment for all measured variables in each of the
three groups (control, primary ARDS, secondary ARDS) was per-
formed with paired t-tests. In order to compare the between groups
differential effects of treatment, we ﬁrst calculated the percentage
difference for each variable by subtracting the baseline value from the
post-treatment one, and then expressing it as percentage of the
baseline. The percentage differences were then compared using one-way analysis of variance followed by post hoc comparisons with the
Bonferroni method.
3. Results
3.1. Cell populations
Under our experimental conditions the cell viability was approxi-
mately 90% for BAL ﬂuid cells and 95% forwhole blood cells. In BAL ﬂuid,
the number of alveolarmacrophageswas similar in ARDS and in control
patients [(2.6±1.06 vs. 2.48±0.8)×106 cells/mLBAL, p-value=0.93)],
respectively, whereas the number of neutrophils increased in ARDS
(8.9±3.0)×106 cells/mL BAL compared to control (1.5±0.5)×106
cells/mL BAL, p-value=0.045. Blood mononuclear cell count did not
differ signiﬁcantly between ARDS and control patients. Moreover,
neither total BAL cell count nor blood monocytes did differ in primary
compared to secondary ARDS.
3.2. Phospholipase A2 total activity
Following stimulation of AMΦ with LPS, total PLA2 activity was
signiﬁcantly increased in the cell homogenate from the control group,
while no such response was detected in the cells from either primary
or secondary ARDS, without any signiﬁcant difference between them.
A similar response was encountered upon challenge with IFNγ. In
particular, an increase in PLA2 was observed in the AMΦ from control
patients, while PLA2 activity in the cells from either ARDS groups was
not signiﬁcantly altered. The difference between primary and
secondary ARDS was not signiﬁcant (Fig. 1, Table 2).
When non-treated AMΦ were incubated with surfactant, we
observed a uniform suppression of PLA2 activity in all control, primary
and secondary ARDS patients by (−46.96±14.00) %, p=0.022,
Table 2
Relative changes in total PLA2 activity following stimulation with LPS or IFN-γ.
LPS INF-γ
Mean p Value 95% CI Mean p Value 95% CI
Alveolar macrophages
Control vs. baseline 34.2 0.0028 16.6 to 51.9 57.6 0.015 10.7 to 104.5
Primary ARDS vs. baseline −16.9 N0.05 −46.4 to 12.7 −14.1 N0.05 −34.2 to 6.0
Secondary ARDS vs. baseline −2.3 N0.05 −9.6 to 4.7 −6.5 N0.05 −18.3 to 5.1
Control vs. primary ARDS 51.1 b0.001 20.6 to 81.7 71.7 b0.01 25.6 to 117.0
Control vs. secondary ARDS 36.7 b0.05 6.0 to 67.1 64.1 b0.01 18.0 to 110.3
Primary vs. secondary ARDS −16.5 N0.05 −46.0 to 17.0 −7.5 N0.05 −53.6 to 38.5
Macrophage supernatants
Control vs. baseline 119.0 0.012 30.7 to 207.2 12.0 N0.05 −6.1 to 30.8
Primary ARDS vs. baseline −7.7 N0.05 −22.3 to 6.7 −1.1 N0.05 −40.1 to 37.8
Secondary ARDS vs. baseline −7.6 N0.05 −19.6 to 43.0 −12.0 N0.05 −33.8 to 9.1
Control vs. primary ARDS 126.0 b0.01 32.5 to 220.9 13.5 N0.5 −28.9 to 55.9
Control vs. secondary ARDS 126.5 b0.01 35.7 to 217.3 24.6 N0.5 −17.8 to 67.1
Primary vs. secondary ARDS −02 N0.05 −96.8 to 96.5 11.1 N0.5 −31.3 to 53.6
Blood monocytes
Healthy volunteers vs. baseline 75.8 b0.01 29.3 to 119.5 40.1 b0.05 21.1 to 60.7
Healthy volunteers vs. control 4.5 N0.5 2.1 to 6.6 0.8 N0.5 −1.8 to 2.2
Control vs. baseline 71.3 b0.01 28.8 to 113.7 39.3 b0.05 21.9 to 56.6
Primary ARDS vs. baseline 111.8 b0.01 34.7 to 188.8 64.4 b0.05 24.9 to 94.2
Secondary ARDS vs. baseline −23.5 N0.05 −49.0 to 2.4 −22.1 N0.05 −45.1 to 0.8
Control vs. primary ARDS −40.4 N0.05 −124.0 to 43.2 −25.2 N0.05 −64.8 to 14.2
Control vs. secondary ARDS 94.7 b0.05 11.1 to 178.5 61.4 b0.01 20.7 to 102.2
Primary vs. secondary ARDS 135.3 b0.01 54.8 to 215.7 86.7 b0.001 48.8 to 124.6
Fig. 2. Relative changes of total PLA2 activity in the supernatants of alveolar
macrophages from primary, secondary ARDS and control patients, after ex vivo
treatment with LPS or IFN-γ. Cells were isolated from the BAL ﬂuid of intubated patients
with primary, secondary ARDS and patients without cardiopulmonary disease
(controls). AMΦ were isolated as described in “Materials and Methods”. After FBS
removal, the cells were treated for 20 hrs with LPS (25 μg/mL) or IFN-γ (300 U/mL).
Extracellular levels of PLA2 activity were determined ﬂuorimetrically in the cell
supernatants. Data are expressed as Mean±SEM of the percent difference between
untreated (baseline) and treated cell supernatants. Statistically signiﬁcant differences
(pb0.05) are marked as follows: (*): Treated vs. Untreated cells;(†): Primary ARDS vs.
Control;( ‡): Secondary ARDS vs. Control. The exact p values are presented in Table 2.
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Moreover, surfactant attenuated the effects of LPS and IFNγ in the
control group and the levels of PLA2 were decreased in both ARDS
groups: In particular, in macrophages from control patients surfactant
prevented the increase of PLA2 induced by LPS, [(4.1±2.2) %, pN0.05].
Additionally, in primary as in secondary ARDS, surfactant caused a
signiﬁcant and consistent decrease in the intracellular levels of PLA2 in
comparison with the untreated cells, by (−64.1±12.9) %, pb0.05 and
(−68.0±22.2) %, pb0.05, respectively. The combination of IFN-γ with
surfactant revealed similar changes: [(7.2±3.1) %, pN0.05, (−84.3±
21.8) %, pb0.01, and (−78.0±19.9) %, pb0.01] for control, primary and
secondary ARDS, respectively. There was not any difference between
primary and secondary ARDS. However, statistically signiﬁcant differ-
ence between PLA2 activity in Control group+LPS or INF-γ+surfactant
vs. LPS or IFN-γ, (pb0.05) was observed (Fig. 1).
In theAMΦ cell supernatants fromcontrol patients upon stimulation
with LPS, a signiﬁcant relative increase in total secreted PLA2 activity
was observed. In contrast, the cells from either ARDS groups did not
respond to the stimulus by secreting PLA2. The difference in the
response between control and ARDS groupswas statistically signiﬁcant.
IFN-γ did not cause any signiﬁcant changes in the supernatants of
alveolar macrophages total PLA2 from either control or ARDS patients.
No differences were observed between control patients and primary or
secondary ARDS, neither between primary nor secondary ARDS (Fig. 2,
Table 2).
Blood monocytes from patients with local lung injury (primary
ARDS), control patients and healthy volunteers responded to LPS and
IFN-γ in a similar manner, by increasing signiﬁcantly PLA2 total levels
within the cells. However, this was not the case for patients with
systemic injury (secondary ARDS), where the monocytes failed to
respond to the stimuli. Ιn particular, LPS caused an increase of PLA2 in
control, healthy volunteers and primary ARDS while in secondary
ARDS there was a non-signiﬁcant decrease. There were no differences
between control and healthy volunteers. The differences between
control and secondary ARDS as well as between primary and
secondary ARDS were statistically signiﬁcant. Similarly, PLA2 relative
changes were signiﬁcantly increased in monocytes from healthy
volunteers, control and primary ARDS patients treated with IFN-γ.
However, in secondary ARDS stimulation with IFN-γ caused a non-signiﬁcant change. The response of healthy volunteers and control
monocytes did not differ from that of primary ARDS but they differed
signiﬁcantly from secondary ARDS. In consistence, primary differed
signiﬁcantly from secondary ARDS (Fig. 3, Table 2).
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invariable under all conditions.
3.3. PLA2 isoenzymes
3.3.1. Cytosolic PLA2
(cPLA2) and its activated-phosphorylated form (p-cPLA2) in AMΦ
from primary, secondary ARDS and control groups of patients were
analysed bywestern blotting. As shown in (Fig. 4), patients with ARDS
did not show any further increase in p-cPLA2 protein levels when
stimulatedwith either LPS or IFN-γ (LPS vs. untreated: p=0.8 and IFN
vs. untreated: p=0.56). It should be mentioned that the untreated
cells from ARDS patients presented persistently elevated p-cPLA2
levels compared to the control patients where the signal was faint
(p=0.03). However, in control patients, treatment with either LPS or
IFN-γ caused a signiﬁcant increase in p-cPLA2 band density (LPS vs.
untreated: p=0.008 and IFN vs. untreated: p=0.03).
Blood monocytes from control, healthy volunteers and primary
ARDS patients responded to treatment by LPS and IFN-γ by elevating
p-cPLA2 protein levels. In secondary ARDS, however, persistently
increased levels of p-cPLA2 were observed, even in the non-treated
cells, which did not change signiﬁcantly after cell stimulation (Fig. 5).
3.3.2. Secretory PLA2 type IIA
Within AMΦ from either ARDS or control groups, sPLA2-IIA was in
non-detectable levels. However, after stimulation with LPS, sPLA2-IIA
was found in low levels only in the AMΦ from control patients. In
contrast, no response was observed in the cells from ARDS patients. InFig. 3. Phospholipase A2 levels in blood monocytes from ARDS and control patients,
after ex vivo treatment with LPS or IFN-γ. Blood monocytes were isolated from the
blood of patients with primary, secondary ARDS and patients without cardiopulmonary
disease (controls). Cells were allowed to adhere for 3 hrs in a complete medium as
described in Materials and methods. Then, FBS was removed and the cells were treated
for 20 h with LPS (25 μg/mL) or IFN-γ (300 U/mL). Intracellular PLA2 activity was
quantiﬁed ﬂuorimetrically in cell homogenates. Data represent the Mean±SEM of the
percent difference between untreated (Baseline) and treated cells. Statistical
signiﬁcance (pb0.05), are marked as follows: (*): Treated cells vs. Untreated;
(#): Secondary ARDS vs. Control; (§): Primary vs. Secondary ARDS.the AMΦ supernatants from both ARDS and control groups a strong
signal of the enzyme was detected after stimulation with LPS. No
signal was obtained in the non-treated cell supernatants. IFN-γ did
not have any effect in sPLA2-IIA secretion from AMΦ (Fig. 6).
Within monocytes there were no detectable levels of sPLA2-IIA,
regardless the group of patients. In monocyte supernatants we found
the enzyme only after challenge with LPS in primary and secondary
ARDS as well as in control group. IFN-γ did not induce any secretion of
sPLA2-IIA in any group of patients (Fig. 6).
3.4. Toll-like receptors 4 expression
Flow-cytometric analysis of TLR4 expression, given in arbitrary
units of Mean Fluorescence Intensity (MFI), was conducted by using
anti-TLR4 (HTA-125) antibody.
Monocytes from control patients showed an up-regulation of the
TLR-4 surface expression after challenge with LPS from (35.3±13.4)
to (52.3±19.0)MFI, representing apercentdifferenceof (50.8±12.0)%,
p value=0.002. Similarly, in primary ARDS the expression changed
from (36.5±14.9) to (57.3±16.6)MFI after LPS stimulation, represent-
ing an increase of (57.0±22.0) %, (pb0.001). However, untreated
monocytes from patients with secondary ARDS had an elevated
expression, (59.7±34.0) MFI, compared to those with primary ARDS.
Treatment with LPS caused a down-regulation of TLR-4 to (42.2±18.0)
MFI, representing a difference of (−25.9±5.0) %, p-value=0.04
(Fig. 7). Monocytes from control patients and healthy volunteers
showed a comparable up-regulation of the TLR-4 surface expression
after challenge with LPS.
TLR4 expression in AMΦ from both control and ARDS groups was
low compared to the relevant expression in monocytes. After LPS
challenge, the alveolar macrophages from control patients displayed
an approximately 50 % increase of TLR4 expression, from (11.1±2.3)
to (21.9±6.8) MFI. In contrast, the expression of TLR4 in the
macrophages from ARDS patients was close to the detection limit of
the method (4.4±2.1) MFI and no signiﬁcant change was observed
after stimulation with LPS.
4. Discussion
We have previously shown that PLA2 activity is increased in the
BAL ﬂuid and cells of ARDS patients, with higher levels occurring in
direct ARDS [12]. This led to the hypothesis that PLA2 production is
related to cells'–mainly alveolar macrophages–stimulation by inﬂam-
matory mediators. The present study focused on the ex vivo
stimulation of alveolar macrophages and blood monocytes from
ARDS and control patients on mechanical ventilation. The major
ﬁndings can be summarized as follows: (1) Alveolar macrophages
from patients with ARDS abated any further PLA2 production and
secretion upon stimulation with LPS or IFN-γ. On the contrary, upon
stimulation with LPS and IFN-γ, macrophages from control patients
showed increased relative changes in intracellular PLA2 activity. Only
LPS caused a signiﬁcant secretion of PLA2. (2) After LPS challenge, the
alveolar macrophages from control patients displayed an increased
TLR4 expression, in contrast to those from ARDS patients where
stimulation with LPS had no effect. (3) Treatment of cells with
exogenous surfactant suppressed total PLA2 activity in both ARDS and
control patients, even in the presence of stimulants. (4) Mononuclear
cells from patients with primary ARDS responded to LPS challenge by
an upregulation of TLR4 expression, as well as by a relative increase in
PLA2 activity, similar to cells from control patients and healthy
volunteers. In contrast, in monocytes from patients with systemic
inﬂammation (secondary ARDS) no PLA2 induction was observed,
while TLR4 expression was down-regulated. (5) The main types
of PLA2 identiﬁed within the cells were cPLA2 and its activated form
p-cPLA2, while the main type of secretory PLA2 was -IIA.
Fig. 4. Immunoblot of cytosolic PLA2 (cPLA2) and its activated-phosphorylated form (p-cPLA2) in alveolar macrophages from patients with primary, secondary ARDS and from
control patients. Alveolar macrophages isolated as described in Materials and methods were treated ex vivo with LPS (25 μg/mL) or IFN-γ (300 U/mL). (A): Immunoblots for cPLA2
and p-cPLA2 were obtained by using polyclonal antibodies and equal protein loading was conﬁrmed by anti-β-actin antibody. They are representative of three independent
experiments. Phosphorylation of cPLA2 was induced only in AMΦ from control patients after stimulation with both LPS and IFN-γ. The cPLA2 and p-cPLA2 bands appeared at 85 and
110 kDa, respectively, while β-actin at 43 kDa. (U): Untreated cells.
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Alveolar macrophages play a signiﬁcant role in the respiratory
tract, exerting pathogen recognition, antigen processing and phago-
cytosis. LPS is one of the most potent microbial initiators of in-
ﬂammation. It acts through Toll-like receptors-4 (TLR-4) and induces
the production of inﬂammatory cytokines via a Myeloid Differentia-
tion Factor 88 (MyD88)-dependent pathway [18,19]. Activation of
cPLA2 by phosphorylation and secretion of sPLA2 can take place during
the above process [5]. In our control patients we observed an up-
regulation of TLR-4 after challenge with LPS, a fact that could be
associated with the observed increase in p-cPLA2. Cytosolic PLA2
contains multiple phosphorylation sites on both tyrosine and serine/
threonine residues; given that the anti-p-cPLA2 antibody used in our
immunoblotting experiments recognizes phosphorylation on serine
505 residues, which is a target for p38 and ERK 1/2, we can assume
that at least in part, the above MAP kinases are involved in the
observed cPLA2 activation.
In contrast to control, alveolar macrophages from our ARDS
patients exhibited reduced responsiveness, similar to the LPS-tolerant
phenotype, that was characterized not only by the inability to increaseFig. 5. Immunoblot for cytosolic PLA2 (cPLA2) and its activated-phosphorylated form (p-cPLA
Cells from patients with primary and secondary ARDS and control patients were subjected to
LPS or IFN-γ. Immunoblots for cPLA2 and p-cPLA2 were obtained by using polyclonal ant
representative of three independent experiments. Monocytes from both control and primary
secondary ARDS, however, there was a persistent increase of p-cPLA2 levels, even in the no
p-cPLA2 bands appeared at 85 and 110 kDa, respectively, while β-actin at 43 kDa. (U): Untintracellular sPLA2-IIA protein production and activity, but also to
secrete this pro-inﬂammatory enzyme. The reduced expression of
TLR-4 in our ARDS patients may explain this effect. LPS-tolerance
refers to transient refractoriness of macrophages and monocytes to
LPS following previous exposure, in terms of cytokines' production,
NF-kB translocation and MAPK activation [20]. It is compatible with
either a down-regulation of surface expression of TLR-4 [21], or a
decreased TLR-4/MyD88 complex formation with subsequent im-
pairment of IRAK-1 activity [22]. Down-regulated cytokine production
from LPS-activatedmonocytes has been previously described in sepsis
and in non-septic shock [23,24]. This is potentially associated to
decreased host defence, since sPLA2s exhibit bactericidal effect in vivo
and in vitro [25,26].
Treatment of alveolar macrophages from patients with normal
lungs with IFN-γ caused, similar to LPS, an increase of PLA2, while in
patients with ARDS there was no response. This is in agreement with
previous reports showing the non-speciﬁc nature of LPS tolerance and
a possible “cross-talk” with the IFN-γ pathway [27].
Although IFN-γ increased the relative changes of intracellular PLA2
activity in control patients, it did not induce a signiﬁcant secretion of
the enzyme, in contrast to LPS. This effect is possibly related to an2) in bloodmonocytes from control patients and those with primary or secondary ARDS.
immunoblotting using anti-p-cPLA2 and anti-cPLA2 antibodies. Cells were treated with
ibodies and equal protein loading was conﬁrmed by anti-β-actin antibody. They are
ARDS patients responded to treatment by LPS and IFN-γ elevating the p-cPLA2 signal. In
n-treated cells, which did not change signiﬁcantly after cell stimulation. The cPLA2 and
reated cells.
Fig. 6. Immunoblot for sectetory PLA2 IIa (sPLA2 IIA) in blood monocyte and alveolar macrophage homogenates after challenge with LPS or IFN-γ as well as in their relevant cell
supernatants. Cells were obtained from control patients and those with primary or secondary ARDS. The sPLA2-IIA band appeared at 14 kDa. (U): Untreated cells.
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already described, [28,29], that leads to the up regulation of intra-
cellular levels of PLA2, but not to secretion.
We showed an induction of cPLA2 activation through phosphor-
ylation on Ser-505 residues in macrophages from control patients
upon stimulation with IFN-γ, whereas in ARDS the enzyme was
already activated and was not further phosphorylated after the chal-Fig. 7. TLR4 surface expression in human bloodmonocytes after challenge with LPS, measured
(HTA 125-PE conjugated) antibody, while a mouse PE-IgG1 isotype control antibody was use
the samples’ respective values. Shadowed areas indicate TLR4 surface expression of untreate
treated cells from control patients and those with primary and secondary ARDS. (B) Relative
are expressed as Mean±SEM of the percent difference. Statistically signiﬁcant differences
Control; (§): Primary vs. Secondary ARDS, (pb0.05).lenge. Our results are in agreement with other reports on the
phosphorylation of Ser-505 and -727 residues of cPLA2 by MAP
kinases after challenge with IFN-γ. In human bronchial epithelial cells
IFN-γ causes a rapid and transient activation of PLA2, probably
engaging the constitutive levels of cPLA2, as well as a more prominent,
of the newly synthesized enzyme. The latter can explain the
persistently elevated p-cPLA2 in our ARDS patients [30].by ﬂow cytometry. Cells were stained for 30 min, at 4 °C in the dark with an anti-hTLR4
d as a negative control. The values of the isotype negative controls were subtracted from
d cells. (A): Representative ﬂow cytometry curves showing TLR-4 expression of the LPS-
difference in TLR-4 surface expression between untreated (baseline) and treated. Data
are marked as follows: (*): Treated vs. Untreated (pb0.01); (‡): Secondary ARDS vs.
993E. Hatzidaki et al. / Biochimica et Biophysica Acta 1802 (2010) 986–994Several studies have established that except from the tensioactive
properties, lung surfactant also plays an immuno-regulatory role,
especially through surfactant proteins A and D (SP-A, SP-D) [31].
Chabot S. and al pointed out that SP-A inhibits sPLA2 activity, which
may play a protective role by maintaining surfactant integrity during
lung injury [32].
However, the surfactant preparation we used is a modiﬁed natural
bovine surfactant lacking SP-A and SP-D [33]. Under our experimental
conditions surfactant eliminated the effect of LPS and IFN-γ and
caused a signiﬁcant decrease of intracellular PLA2 activity in
macrophages from both ARDS and control groups, despite the lack
of SP-A and SP-D. This indicates that additional surfactant compo-
nents, such as phospholipids, could play an immunomodulatory role
on both stimulated and non-stimulated alveolar macrophages. In fact,
phosphatidylglycerol, a major phospholipid constituent of surfactant,
suppresses sPLA2-IIA expression in alveolar macrophages [34] and
inhibits in vitro PAF, a potent pro-inﬂammatory mediator [35]. In
agreement, it has been shown that surfactant has the ability to down-
regulate the expression of inﬂammatory cytokines in human alveolar
macrophages stimulated by LPS [36].
4.2. Blood monocytes
Monocytes from patients with primary ARDS responded to stimuli
by increasing PLA2 in a similar manner as those from patients without
pulmonary disease or systemic inﬂammation. However, according to
our ﬁndings, in secondary ARDS none of the activators brought about
any relative change in PLA2 activity, signifying an impaired response.
At least for LPS, this impairment could be attributed to the observed
down regulation of TLR4 on the monocytes surface. Our results
indicated that in primary ARDS the local production of inﬂammatory
mediators in the lung did not have a systemic effect. Interestingly, a
compartmentalization of inﬂammatory response after administration
of LPS has been noticed in animal models [37] although other studies
suggest that pulmonary injury can be associatedwith a systemic effect
[38].
Our ﬁndings support the concept of down-regulated immune
response early in the course of ARDS that appears to be compartmen-
talized in direct (primary), but systemic in indirect (secondary) lung
injury. Despite the intense inﬂammatory reaction during early ARDS,
alveolar macrophages and blood monocytes appear to be functionally
tolerant to stimulants, at least in regard to PLA2 production and TLR4
expression. This could be related to either a state of mixed in-
ﬂammatory responsewith the simultaneous presence of pro- and anti-
inﬂammatory mediators, or to an “exhaustion” of the innate immune
system. The differentiation in the AMΦ response between ARDS and
control patients in regard with PLA2 induction upon LPS challenge
suggests that the enzyme can possibly serve as a surrogate marker of
inﬂammation and the immunity status in ARDS. High sPLA2 serum
levels indicate the risk of developing multiple organ failure in trauma
and surgical patients [39,40] and the risk of coronary events due to
atherosclerosis [41]. Secretory PLA2-IIA is involved in sepsis and in
lung it derives mainly from alveolar macrophages [20].
ALI/ARDS as a syndrome with diverse etiological characteristics is
associated with activation of multiple different albeit cross-talking
pathways that may modify the course of the syndrome towards
resolution or perturbation. Time-dependence is an important charac-
teristic of the interplay between anti-inﬂammatory and pro-inﬂam-
matory substances. Early ARDS is characterized by acute, intense
inﬂammation and edema while persistent, non-resolving ARDS by
ongoing inﬂammation, cell proliferation and ﬁbrosis [1]. It remains
uncertain whether the inﬂammatory reaction is exclusively detri-
mental as it interferes with both the antimicrobial defence and with
the subsequent tissue repair mechanisms [42]. Although unresolving
ARDS has been associated with accelerated systemic inﬂammation
and glucocorticoid resistance [43], several trials of corticosteroids inearly ARDS have failed to show a clear survival beneﬁt and preventive
steroids are probably related with increased ARDS incidence [44].
Corticosteroids are potent inhibitors of PLA2 and modify the tran-
scription rate of the nuclear factor-kΒ, which is an essential com-
ponent of the signalling pathways inducing PLA2 expression and
biosynthesis [45]. Our data on PLA2 activity and TLR4 expression after
stimulation of alveolar macrophages andmonocytes provide evidence
for tolerance and possibly inappropriately down-regulated innate
immunity in early ARDS. An early and precise prediction of im-
munosuppression would allow amore efﬁcient and targeted timing of
immunomodulatory interventions in ARDS [43]. This could explain
why the non-selective inhibitors of PLA2 have been failed in the
prevention of acute respiratory distress syndrome in critically ill
adults as well in the treatment of established ARDS [46]. The complex
pathophysiology of ARDS greatly interferes with the design of clinical
trials and affects both the patients’ outcome. The use of biological
markers such as PLA2 activity and isoenzymes could potentially
facilitate a more efﬁcacious stratiﬁcation and homogeneous selection
of patients in treatment groups [47].
One limitation of this study could be related with the effect of
mechanical ventilation, which can cause ventilator induced lung
injury, especially at high tidal volumes. In animal models with sepsis-
induced ALI it was observed that high tidal volumes up-regulated TLR-
4 and IRAK-3 [48] in lung tissue. However, in the present study all the
patients were ventilated with a protective type of mechanical ven-
tilation using low tidal volume and PEEP. Moreover, we used the same
therapeutic procedure for all patients, so, it seems that mechanical
ventilation did not inﬂuence the relative changes. In particular,
steroids or other anti-inﬂammatory agents were not used until the
sampling time.
In conclusion, various types of PLA2 are engaged in the activation
of macrophages induced by LPS and IFN-γ. Patients with both primary
and secondary ARDS present a compromised responsiveness to
immuno-stimulants locally in the lung, associated with a down-
regulation of TLR4. In blood monocytes from patients with secondary
ARDS (i.e. in sepsis) there was observed a TLR4 down-regulation and
inability of stimulants to induce or activate PLA2, but this was not the
case in early primary ARDSwhere themonocytes responded typically.
Our results point out certain differences in the pathogenetic mech-
anisms of ARDS, related to the risk factor, which highlight the role of
surfactant in controlling inﬂammation in ARDS patients. Finally, PLA2s
could be used as reliable markers of the macrophage immune
competence in ARDS patients.
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